NCT02194335已完成1 期
A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study (Parallel Groups) in Healthy Male and Female Volunteers After Oral Administration of BIBN 4096 BS Drinking Solution (Dosage: 20 - 200 mg)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
The objective of the present study was to obtain information about safety, tolerability and pharmacokinetics of BIBN 4096 BS after oral administration of increasing doses in healthy male and female volunteers. With respect to pharmacokinetics, it was of particular importance to investigate whether therapeutic plasma levels (for treatment of migraine) could have been achieved by oral administration of a BIBN 4096 BS formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants should be healthy males and females
- •Age range from 21 to 50 years
- •Broca Index: within +- 20% of their normal weight
- •Subsequently each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead Electrocardiogram (ECG). Hematopoietic, hepatic and renal function test will be carried out in the laboratory. The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first administration of the test substance. In accordance with Good Clinical Practice (GCP) and local legislation all volunteers will have given their written informed consent prior to admission to the study
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study (exclusion: substitution therapy regarding thyroid gland and/or ovaries)
- •Use of any drugs which might influence the results of the trial (within one week prior to administration or during the trial)
- •Participation in another study with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on study days
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood donation (>= 100 ml) within four weeks prior to administration or during the trial
- •Excessive physical activities (within the last week before the study)
- •Any laboratory value outside the reference range of clinical relevance
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraceptives, sterilization, intrauterine pessary (IUP)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
BIBN 4096 BS - in single rising doses
Experimental
干预措施: BIBN 4096 BS - in single rising doses (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: up to 24 days
Number of patients with abnormal changes in laboratory parameters
时间窗: up to 8 days after drug administration
Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)
时间窗: up to 8 days after drug administration
Number of patients with clinically significant changes in 12-lead Electrocardiogram (ECG)
时间窗: up to 8 days after drug administration
次要结局
- AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 24 hours after drug administration)
- CL/F (Apparent clearance of the analyte in plasma following extravascular administration)(up to 24 hours after drug administration)
- MRTtot (Total mean residence time of the analyte in plasma)(up to 24 hours after drug administration)
- Vz/F (Apparent volume of distribution of the analyte during the terminal phase)(up to 24 hours after drug administration)
- AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)(up to 24 hours after drug administration)
- Terminal rate constant in plasma(up to 24 hours after drug administration)
- tmax (Time from dosing to the maximum concentration of the analyte in plasma)(up to 24 hours after drug administration)
- Cmax (Maximum measured concentration of the analyte in plasma)(up to 24 hours after drug administration)
- t½ (Terminal half-life of the analyte in plasma)(up to 24 hours after drug administration)
研究者
相似试验
已完成
1 期
Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194348Boehringer Ingelheim12
已完成
1 期
Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female VolunteersHealthyNCT02199860Boehringer Ingelheim63
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194777Boehringer Ingelheim48
已完成
1 期
Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194322Boehringer Ingelheim38
已完成
1 期
Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02198326Boehringer Ingelheim32